Brevan Howard Capital Management LP Denali Therapeutics Inc. Transaction History
Brevan Howard Capital Management LP
- $13.9 Billion
- Q4 2024
A detailed history of Brevan Howard Capital Management LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 17,917 shares of DNLI stock, worth $371,419. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,917
Previous 11,161
60.53%
Holding current value
$371,419
Previous $325,000
12.31%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DNLI
# of Institutions
241Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$273 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$255 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$249 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$204 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$114 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.78B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...